Özet:

Objective: As paratesticular masses constitute 2-3% of all scrotal and inguinal masses, published cases in the literature are limited. We aimed to present our experiences of nine cases that we have treated and followed up in our department. Methods: Between January 2013 and February 2017, we retrospectively analyzed the data of nine patients with paratesticular mass in our department. Results: Seven (77.8%) patients presented with scrotal mass or swelling, while two (22.2%) patients had swelling in the inguinal region. Histological types of malignant tumors were rhabdomyosarcoma [(RMS), 2 cases, 22.3%)], liposarcoma [(LPS), 1 case, 11.1%)], leiomyosarcoma [(LMS), 1 case, 11.1%)] and malignant fibrous histiocytoma [(MFH), 1 case, 11.1%)]. Bening tumors were fibroma (1 case, 11. 1%), adenomatoid tumor (1 case, 11.1%), cystadenoma (1 case, 11.1%) and inflammatory myophibroblastic tumor (1 case, 11.1%). During median 23.5 (4-62) months of follow-up of paratesticular sarcomas, the rates of recurrence-free and progressionfree survival were 60%, the overall survival rate was 60%. LMS and MFH had poor prognosis. No recurrence or progression was observed in the follow-up of LPS and RMS. Among them, LPS had the best prognosis.The disease-free survival was 100% at the median 49 (36-64) months follow-up of four benign masses without any need for adjuvant treatment. According to FNCLCC Classification, times of local recurrence-free survival and overall survival in grade II sarcomas were significantly higher than those with grade III (p=0.039). Conclusion: It is difficult to differentiate clinically benign paratesticular masses from sarcomas. LPS has better prognosis and high-grade sarcomas have poor prognosis. If adjuvant treatments are not added, local recurrence or progression may be observed in a short time.